Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
400
NCT02439359
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2015
Completion: Dec 31, 2015
NCT03163446
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
Phase: Phase 2
Start: May 23, 2017
Completion: Mar 7, 2019
NCT04160468
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
Phase: Phase 3
Start: Dec 20, 2019
Completion: Sep 9, 2022